Literature DB >> 34098080

Selective ability of rat 7-Dehydrocholesterol reductase (DHCR7) to act on some 7-Dehydrocholesterol metabolites but not on lumisterol metabolites.

Robert C Tuckey1, Edith K Y Tang2, Yunzhi A Chen2, Andrzej T Slominski3.   

Abstract

7-Dehydrocholesterol reductase (DHCR7) catalyses the final step of cholesterol biosynthesis in the Kandutsch-Russel pathway, the reduction of 7-dehydrocholesterol (7DHC) to cholesterol. 7DHC can be acted on by a range of other enzymes including CYP27A1 and CYP11A1, as well as by UVB radiation, producing a number of derivatives including hydroxy-metabolites, some of which retain the C7-C8 double bond and are biologically active. These metabolites include lumisterol (L3) which is a stereoisomer of 7DHC produced in the skin by UVB radiation of 7DHC, as well as vitamin D3. The aim of this study was to test whether these metabolites could act as substrates or inhibitors of DHCR7 in rat liver microsomes. To initially screen the ability of these metabolites to interact with the active site of DHCR7, their ability to inhibit the conversion of ergosterol to brassicasterol was measured. Sterols that significantly inhibited this reaction included 7DHC (as expected), 20S(OH)7DHC, 27(OH)DHC, 8DHC, 20S(OH)L3 and 22(OH)L3 but not 7-dehydropregnenolone (7DHP), 25(OH)7DHC, L3 or vitamin D3 and its hydroxyderivatives. Sterols that inhibited ergosterol reduction were directly tested as substrates for DHCR7. 20S(OH)7DHC, 27(OH)DHC and 7-dehydrodesmosterol were confirmed to be substrates, giving the expected product with the C7-C8 double bond removed. No products were observed from 8DHC or 20S(OH)L3 indicating that these sterols are inhibitors and not substrates of DHCR7. The resistance of lumisterol and 7DHP to reduction by DHCR7 in cells will permit other enzymes to metabolise these sterols to their active forms retaining the C7-C8 double bond, conferring specificity to their biological actions.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  7-dehydrocholesterol reductase; 7-dehydropregnenolone; DHCR7; Lumisterol; Vitamin D3

Mesh:

Substances:

Year:  2021        PMID: 34098080      PMCID: PMC8403650          DOI: 10.1016/j.jsbmb.2021.105929

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   5.011


  49 in total

1.  Microsomal enzymes of cholesterol biosynthesis from lanosterol. Solubilization and purification of steroid 8-isomerase.

Authors:  Y K Paik; J T Billheimer; R L Magolda; J L Gaylor
Journal:  J Biol Chem       Date:  1986-05-15       Impact factor: 5.157

2.  Chemical synthesis of 7- and 8-dehydro derivatives of pregnane-3,17alpha,20-triols, potential steroid metabolites in Smith-Lemli-Opitz syndrome.

Authors:  Li-Wei Guo; William K Wilson; Jihai Pang; Cedric H L Shackleton
Journal:  Steroids       Date:  2003-01       Impact factor: 2.668

Review 3.  The biological synthesis of cholesterol.

Authors:  K Bloch
Journal:  Science       Date:  1965-10-01       Impact factor: 47.728

4.  Chemical synthesis of 20S-hydroxyvitamin D3, which shows antiproliferative activity.

Authors:  Wei Li; Jianjun Chen; Zorica Janjetovic; Tae-Kang Kim; Trevor Sweatman; Yan Lu; Jordan Zjawiony; Robert C Tuckey; Duane Miller; Andrzej Slominski
Journal:  Steroids       Date:  2010-06-11       Impact factor: 2.668

5.  Photosynthesis of previtamin D3 in human skin and the physiologic consequences.

Authors:  M F Holick; J A MacLaughlin; M B Clark; S A Holick; J T Potts; R R Anderson; I H Blank; J A Parrish; P Elias
Journal:  Science       Date:  1980-10-10       Impact factor: 47.728

6.  Vitamin D derivatives enhance cytotoxic effects of H2O2 or cisplatin on human keratinocytes.

Authors:  Anna Piotrowska; Justyna Wierzbicka; Tomasz Ślebioda; Michał Woźniak; Robert C Tuckey; Andrzej T Slominski; Michał A Żmijewski
Journal:  Steroids       Date:  2016-04-13       Impact factor: 2.668

7.  Dehydrosteroid measurements in maternal urine or serum for the prenatal diagnosis of Smith-Lemli-Opitz syndrome (SLOS).

Authors:  Cedric H L Shackleton; Josep Marcos; Glenn E Palomaki; Wendy Y Craig; Richard I Kelley; Lisa E Kratz; James E Haddow
Journal:  Am J Med Genet A       Date:  2007-09-15       Impact factor: 2.802

8.  Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells.

Authors:  Michal A Zmijewski; Wei Li; Jordan K Zjawiony; Trevor W Sweatman; Jianjun Chen; Duane D Miller; Andrzej T Slominski
Journal:  Steroids       Date:  2008-11-06       Impact factor: 2.668

9.  Protective effects of novel derivatives of vitamin D3 and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms.

Authors:  Anyamanee Chaiprasongsuk; Zorica Janjetovic; Tae-Kang Kim; Stuart G Jarrett; John A D'Orazio; Michael F Holick; Edith K Y Tang; Robert C Tuckey; Uraiwan Panich; Wei Li; Andrzej T Slominski
Journal:  Redox Biol       Date:  2019-04-20       Impact factor: 11.799

Review 10.  Novel vitamin D photoproducts and their precursors in the skin.

Authors:  Andrzej Slominski; Tae-Kang Kim; Michal A Zmijewski; Zorica Janjetovic; Wei Li; Jianjun Chen; Ekaterina I Kusniatsova; Igor Semak; Arnold Postlethwaite; Duane D Miller; Jordan K Zjawiony; Robert C Tuckey
Journal:  Dermatoendocrinol       Date:  2013-01-01
View more
  2 in total

1.  Editorial: Steroids and Secosteroids in the Modulation of Inflammation and Immunity.

Authors:  Andrzej T Slominski; Bidesh Mahata; Chander Raman; Oxana Bereshchenko
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

2.  Metabolic activation of tachysterol3 to biologically active hydroxyderivatives that act on VDR, AhR, LXRs, and PPARγ receptors.

Authors:  Andrzej T Slominski; Tae-Kang Kim; Radomir M Slominski; Yuwei Song; Zorica Janjetovic; Ewa Podgorska; Sivani B Reddy; Yuhua Song; Chander Raman; Edith K Y Tang; Adrian Fabisiak; Pawel Brzeminski; Rafal R Sicinski; Venkatram Atigadda; Anton M Jetten; Michael F Holick; Robert C Tuckey
Journal:  FASEB J       Date:  2022-08       Impact factor: 5.834

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.